EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden

Qing Liu, Omid Sadr-Azodi, Lars Engstrand iD, Katja Fall, Nele Brusselaers iD

Helicobacter · 2024

DOI: 10.1111/hel.70001 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Helicobacter, 2024. Verfasst von Qing Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Helicobacter pylori ( H. pylori ) is an established gastric carcinogen, also associated with an increased risk of colorectal cancer. Therefore, we suspected that H. pylori eradication lowers the risk of colorectal cancer. Material and Methods We assessed if H. pylori eradication therapy is associated with a reduced risk of colorectal adenocarcinoma in a population‐based nationwide cohort study. This study included all Swedish adults with at least one recorded H. pylori eradication episode between July 2005 and December 2012, based on the high‐quality Swedish health registries. Colorectal adenocarcinoma risks were compared to the Swedish background population, presented as standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), accounting for age, sex, calendar period, tumor location (left or right sided), stage, and number of eradication episodes, from 1 year after eradication and onward.

Results

Among 80,381 individuals receiving H. pylori eradication therapy (average follow‐up 4.1 years), 282 were diagnosed with colorectal cancer (97.2% adenocarcinoma). Overall, H. pylori eradication was associated with an elevated risk of colorectal adenocarcinoma (SIR 1.27, 95% CI: 1.12–1.43). The colorectal adenocarcinoma risk was increased 1–2 years after eradication (SIR 1.42, 95% CI: 1.17–1.72), then decreased 2–4 years (SIR 0.80, 95% CI: 0.65–0.98) and 4–6 years (SIR 0.76, 95% CI: 0.57–0.99), yet not ≥ 6 years (SIR 1.36, 95% CI: 0.78–2.21) after eradication compared to the general population. Overall, right‐sided (SIR 1.47, 95% CI: 1.21–1.76) and left‐sided (SIR 1.35, 95% CI: 1.09–1.67) colon adenocarcinomas risks were higher among eradicated individuals than the general population.

Conclusion

H. pylori eradication was not associated with a clear and consistent reduction of colorectal cancer in our Swedish cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHelicobacter InfectionsHelicobacter pyloriHumansSwedenMaleFemaleMiddle AgedAgedCohort StudiesAdultAdenocarcinomaAnti-Bacterial AgentsIncidenceAged, 80 and overYoung AdultAdolescent

Stichwörter der Autor:innen

Helicobacter pylori eradication therapyantibioticscancer riskcolorectal adenocarcinomaproton pump inhibitors

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Surgery, Capio Saint Göran Hospital, Stockholm, Sweden.
  • Clinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Global Health Institute, University of Antwerp, Antwerp, Belgium.

ORCID-Profile: Lars Engstrand, Nele Brusselaers

Förderung

  • China Scholarship Council
  • Vetenskapsrådet

Zitieren

APA

Liu, Q., Sadr-Azodi, O., Engstrand, L., Fall, K., & Brusselaers, N. (2024). Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. https://doi.org/10.1111/hel.70001

Vancouver

Liu Q, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden. Helicobacter. 2024. doi:10.1111/hel.70001

BibTeX
@article{Liu2024,
  author = {Liu, Qing and Sadr-Azodi, Omid and Engstrand, Lars and Fall, Katja and Brusselaers, Nele},
  title = {Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population‐Based Nationwide Cohort Study in Sweden},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.70001}
}
Kostenlos starten →